Strug­gling Ova­Science re­or­ga­nizes, stock plunges; Chugai inks €130M deal; Iron­wood, Al­ler­gan re­port new lina­clotide CR2 da­ta

• With its fer­til­i­ty game plan strug­gling, Waltham, MA-based Ova­Science says it will chop out 30% of its staff to help re­duce ex­pens­es and ex­tend its cash run­way. New CEO Har­ald Stock and COO Paul Chap­man are out the door as well, sig­nal­ing the kind of tur­moil that in­vestors hate. The com­pa­ny’s stock $OVAS plunged 29% this morn­ing as found­ing CEO Michelle Dipp stepped back in to over­see the com­pa­ny as it re­or­ga­nized and looked for a new CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER